Efficacy of liraglutide on metabolic parameters and pregnancy in polycystic ovary syndrome patients combined with impaired glucose tolerance and obesity

Objective To investigate the efficacy of liraglutide in metabolic parameters and pregnancy situations on polycystic ovary syndrome (PCOS) combined with impaired glucose tolerance and obesity. Methods A total of 177 patients who diagnosed as PCOS combined with impaired glucose tolerance, obesity and infertility were collected in this study from March 2011 to March 2014. They were randomly divided into liraglutide group ((28±7) yrs) and control group ((27±7) yrs). Patients in control group were treated with metformin (0.5 g, tid) and the liraglutide group were treated with metformin (0.5 g, tid) and liraglutide (1.2-1.8 mg/d). The body weight, blood biochemical patametres and sex hormone levels were detected at 0, 12, 24 weeks after treatment. Independent-samples t test and Chi-square were used for statics. Results (1) The body weight, waist circumference and BMI were significantly improved in both groups after treatment for 12 and 24 weeks. Compared with the control group, the body weight, waist circumferences, body mass index (BMI) were significantly decreased in liraglutide group (t=10.11-19.97, all P<0.01). (2) Compared with the control group, 2 - hour postprandial blood glucose (2 hPG) and glycated hemoglobin A1c(HbA1c) were significantly decreased in Liraglutide-group ((7.5±1.2) vs (8.0±1.1) mmol/L, (5.5±0.8)% vs (6.0±0.3)%,t=31.61, 21.93, both P<0.05). (3) The level of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein-cholesterol (LDL-C) were decreased in Liraglutide group than the control group after 24 weeks (t=13.44- 21.56, all P<0.05). (4) The level of testeserone (T), luteinizing hormone (LH), follicule- stimulating hormone (FSH) were decreased in liaglutide group after 12 weeks and 24 weeks than the control group (at 24 weeks, TSH (4.2±0.4) vs (5.0±0.6) U/L, LH (6.1±1.4) vs (8.2±1.2) U/L,t= 13.72, 204.3, both P< 0.05). (5) The measurements of fasting insulin (FINS), homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) were decreased while the HOMA-β was increased in liraglutide group after 12 weeks and 24 weeks (t=20.75- 35.78, all P<0.05). (6) In Liraglutide-group, changes of the menstrual cycle, temperature and natural conception odds were significantly increased in comparison to the control group (86.2% (75/87) vs 70.5% (60/85), 78.1% (68/87) vs 50.5% (43/85), 42.5% (37/87) vs 22.3% (19/85), χ2=10.769, 14.281, 7.97, all P<0.05). Conclusion Liraglutide may effectively reduce body weight, improve glucose- lipid metabolism and the level of sex hormones. Furthermore, liraglutide may also promote the natural pregnancy rate. Key words: Polycysticovarysyndrome; Impairedglucosetolerance; Obesity; Infertility; Liraglutide